| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 04/09/2008 | CN101156853A Hydrochloric acid glitazone dispersion piece and its preparation method |
| 04/09/2008 | CN101156847A Usage of purplish plastocyanin as insulin sensitization agent as well as its preparation |
| 04/09/2008 | CN100379412C Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia |
| 04/08/2008 | US7355069 2-[2-(4-{2-[ethyl(2-fluorobenzyl)amino]-2-oxoethoxy}phenyl)ethoxy]benzoic acid; peroxisome proliferator-activated receptors alfa agonist; antidiabetic, hypotensive agent; obesity, elevated VLDL (Very Low Density Lipoproteins) and reduced HDL (High Density Lipoprotein) concentrations |
| 04/08/2008 | US7355054 Indole derivatives |
| 04/08/2008 | US7355049 Biaryloxymethylarenecarboxylic acids as glycogen synthase activator |
| 04/08/2008 | US7355024 Regulatory sequences for modulation of INGAP expression and reporter constructs |
| 04/08/2008 | US7354919 Isoxazole compositions useful as inhibitors of ERK |
| 04/08/2008 | US7354728 Coactivation of nuclear receptors |
| 04/03/2008 | WO2008038692A1 Diaryl ketimine derivative |
| 04/03/2008 | WO2008037746A1 Pyridooxazepine progesteron receptor modulators |
| 04/03/2008 | WO2008021338A3 Tricyclic oxazolidone derivatives useful as pr modulators |
| 04/03/2008 | US20080081825 5-((2,4-difluorophenyl) {[(1-methyl-4-piperidinyl)oxy]imino}methyl)-1-(2,6-dimethylphenyl)-2(1H)-pyridinone; p38 MAP kinase and tumor necrosis factor inhibitor; inflammatory cytokines or chemokine, respiratory diseases, cardiovascular diseases and bone diseases |
| 04/03/2008 | US20080081787 stable aqueous solution containing endogenous growth hormone secretagogues having pH range of 2 to 7; a pH adjuster or a buffer agent; nondegradation, storage stability; biodrug inducing the secretion of growth hormone |
| 04/03/2008 | CA2664358A1 Diarylketimine derivative |
| 04/03/2008 | CA2664120A1 Pyridooxazepine progesteron receptor modulators |
| 04/02/2008 | EP1905782A1 Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
| 04/02/2008 | EP1905771A2 Quinuclidine derivatives and their use |
| 04/02/2008 | EP1904075A2 Extracts from epimedium species method for production and use thereof |
| 04/02/2008 | EP1904028A1 Estrogen compositions for vaginal administration |
| 04/02/2008 | CN101155598A Method of treating or preventing type-2 diabetes |
| 04/02/2008 | CN101153042A Thienopyrimidine compound and use of the same |
| 04/02/2008 | CN101152511A Medicament for treating hyperthyroidism disease and method of preparing the same |
| 04/02/2008 | CN101152360A Traditional Chinese medicine for treating adverse effect of mammary cancer endocrine |
| 04/02/2008 | CN100378116C High purity composition comprising (7a, 17a,)-17-hydroxy-7-methyl 19-nor-17-prege-5-(10)-en-20-yn-3-one |
| 04/02/2008 | CN100377711C Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol |
| 04/02/2008 | CN100377710C Aromatase inhibition to enhance assisted reproduction |
| 04/01/2008 | CA2303817C 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) and its use as medicament for treating excess of glucocorticoids |
| 04/01/2008 | CA2175992C In situ modification and manipulation of stem cells of the central nervous system |
| 03/27/2008 | WO2008036271A1 Formulations for therapeutic administration of thyroid stimulating hormone (tsh) |
| 03/27/2008 | WO2007038829A8 Method of drug design |
| 03/27/2008 | US20080076943 4-(Hydroxymethyl)-2,6-dimethoxyphenylboronic acid chemical intermediate for preparing corticotropin-releasing factor receptor antagonists |
| 03/27/2008 | US20080076794 Hyperaldosteronism |
| 03/27/2008 | US20080076778 PARP (poly-ADP ribose polymerase); drug screening; computer networks |
| 03/27/2008 | US20080076768 Pharmaceutical compounds |
| 03/27/2008 | US20080076759 Therapeutic Heterocyclic Compounds 507 |
| 03/27/2008 | US20080075782 Comprising a stabilizing polyol and a bioactive agent, wherein the composition provides quick release of the bioactive agent after administration; inhalation through the mouth; drug delivery; osteoporosis treatment |
| 03/27/2008 | CA2663323A1 Formulations for therapeutic administration of thyroid stimulating hormone (tsh) |
| 03/27/2008 | CA2663242A1 Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors |
| 03/27/2008 | CA2646911A1 2- substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof |
| 03/26/2008 | EP1903045A1 Pyrazolopyrimidine derivative |
| 03/26/2008 | EP1902049A2 Non-steroidal progesterone receptor modulators |
| 03/26/2008 | EP1901770A2 Methods for treatment of growth disorders |
| 03/26/2008 | EP1901737A1 Use of a steroid sulphatase inhibitor for inhibiting the synthesis of androstenedione and/or testosterone |
| 03/26/2008 | CN101151048A Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| 03/26/2008 | CN101151045A Methods for suppressing neovascularization using EphrinB2 |
| 03/26/2008 | CN101151026A O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof |
| 03/26/2008 | CN101148642A Probiotic/non-probiotic combinations |
| 03/26/2008 | CN100376573C 1,3-dihydroimidazole fused-ring compound |
| 03/26/2008 | CN100376560C New tricyclic compounds and their use as medicine, process for their preparation and pharmaceutical compositions containing them |
| 03/26/2008 | CN100376530C Vitamin D analogues |
| 03/26/2008 | CN100376289C Use of HCG and LH in controlled ovarian hyperstimulation |
| 03/26/2008 | CN100376288C Improvement of T cell mediated immunity |
| 03/26/2008 | CN100376267C Pharmaceutical formulation consisting of plant extract with calcium coating |
| 03/26/2008 | CN100376248C Composition containing resveratrol and resveratr-glycoside and its use |
| 03/26/2008 | CN100376246C Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| 03/25/2008 | US7348431 Receptor or non-receptor; 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano) benzo[ alpha ][8]annulenes; anticarcinogenic, antidiabetic, antiproliferative agents; autoimmune and Crohn's diseases, acromegaly, aging resistance; coadminister tamoxifen, raloxifene, taxol, trastuzumab, tirofiban or a COX-2 inhibitor |
| 03/25/2008 | US7348426 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 03/25/2008 | US7348359 Retinoid X receptor modulators |
| 03/25/2008 | US7348318 α-Amino-N-(diaminophosphinyl)lactam derivatives |
| 03/25/2008 | US7348138 Diagnostic methods and kits for identifying individuals exposed to West Nile virus or other viruses including Flavivirus or Pestivirus |
| 03/25/2008 | CA2419077C A method of treating a systemic disease |
| 03/25/2008 | CA2295455C Process for the preparation of mometasone furoate |
| 03/20/2008 | WO2008033851A2 Use of 2-6- (3-amino-piperidin-l-yl) -3-methyl-2, 4-dioxo-3, 4-dihydr0-2h-pyrimidin-1-ylmet hyl-4-fluoro-benzonitrile |
| 03/20/2008 | WO2008033304A2 Compositions for promoting non-leaky collateral vascularization |
| 03/20/2008 | WO2008031734A1 5-phenyl-nicotinamide derivatives |
| 03/20/2008 | WO2008008608A3 Method of treating and preventing secondary hyperparathyroidism |
| 03/20/2008 | US20080071066 Heparin binding protein for use in controlling angiogenesis and as wound healing agent |
| 03/20/2008 | US20080071065 Fibroblast Growth Factor-Like Polypeptides |
| 03/20/2008 | US20080070922 DDPIV inhibitor: selected from (S)-1-{2-[5-cyanopyridin-2yl)amino]ethyl-aminoacetyl)-2-cyano-pyrrolidine, vildagliptin, Sitagliptin, saxagliptin; PDGF receptor tyrosine kinase inhibitor: selected from imatinib, imatinib methanesulfonate; impaired glucose metabolism; impaired glucose tolerance |
| 03/20/2008 | US20080070880 Specific glucocorticosteroid compound having anti-inflammatory activity |
| 03/20/2008 | US20080069861 Gastrointestinal health |
| 03/20/2008 | US20080069841 Pharmaceutical Compositions Containing Botulinum Neurotoxin A2 |
| 03/20/2008 | CA2663279A1 Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,-4-dioxo-3,4-dihydro-2h-pyridimin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer,autoimmune disorders and hiv infection |
| 03/20/2008 | CA2662409A1 5-phenyl-nicotinamide derivatives |
| 03/19/2008 | EP1899305A1 Helix 12 directed non-steroidal antiandrogens |
| 03/19/2008 | EP1898924A1 Methods of treating osteoporosis and secondary hyperparathyroidism using 20-methyl, gemini vitamin d3 compounds |
| 03/19/2008 | EP1682122B1 Combinations of valsartan, amiloride or triamterine, and a diuretic |
| 03/19/2008 | EP1628979B1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors |
| 03/19/2008 | EP1530573B1 Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| 03/19/2008 | EP1513545B1 Methods and means to promote gut absorption |
| 03/19/2008 | CN101143221A Central airway administration for systemic delivery of therapeutics |
| 03/18/2008 | US7345096 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 03/13/2008 | WO2008029763A1 Prostaglandin fat emulsion, method for producing the same, method for stabilizing the same, and emulsifying agent |
| 03/13/2008 | WO2008029511A1 Insulin sensitivity improving agent |
| 03/13/2008 | US20080064668 Carbon 20 is substituted with methyl or cyclopropyl, carbon 16 is a single or double bond, and carbon 23 is a single, double, or triple bond; side effect reduction; vitamin deficiency; anticarcinogenic antiarthritic agents; immunotherapy; metabolic disorders; gene expression inhibition of ILT3 |
| 03/13/2008 | US20080064651 A 21-base antisense oligonucleotide which inhibits gene expression of testosterone-repressed prostate message-2 by tumor cells; prostate and renal cell cancer; enhanced chemosensitivity, hormone and radiation sensitivities |
| 03/13/2008 | CA2661878A1 Anti-activin a antibodies and uses thereof |
| 03/12/2008 | EP1897560A1 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| 03/12/2008 | EP1897559A1 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| 03/12/2008 | EP1897553A1 Inhibitor of stem cell proliferation and uses thereof |
| 03/12/2008 | EP1896481A2 Heterocyclic spiro-compounds as aldosterone synthase inhibitors |
| 03/12/2008 | EP1896465A1 Heterocyclic non-peptide gnrh antagonists |
| 03/12/2008 | EP1896078A1 Estrogen compositions for vaginal administration |
| 03/12/2008 | EP1895999A1 Use of non-steroidal progesterone receptor modulators |
| 03/12/2008 | EP1414809B1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 03/12/2008 | EP1265648B1 NOVEL collagen-BASED MATERIAL WITH IMPROVED PROPERTIES FOR USE IN HUMAN AND VETERINARY MEDICINE AND THE METHOD OF MANUFACTURING SUCH |
| 03/12/2008 | EP0614374B2 MURINE MONOCLONAL ANTIBODY (5c8) RECOGNIZES A HUMAN GLYCOPROTEIN ON THE SURFACE OF T-LYMPHOCYTES |
| 03/12/2008 | CN100374421C 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 03/12/2008 | CN100374139C Chinese medicine compound preparation for treating hyperthyoidism |